Advance Search
YAN Zeying, SUN Haimin, CHEN Yu. Clinical observation of venetoclax in treatment of relapsed or refractory acute myeloid leukemia[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 91-94. DOI: 10.7619/jcmp.20214194
Citation: YAN Zeying, SUN Haimin, CHEN Yu. Clinical observation of venetoclax in treatment of relapsed or refractory acute myeloid leukemia[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 91-94. DOI: 10.7619/jcmp.20214194
shu

Clinical observation of venetoclax in treatment of relapsed or refractory acute myeloid leukemia

  • Department of Hematology, Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University, Shanghai, 200025

More Information
  • Received Date: October 25, 2021
  • Available Online: March 10, 2022
  • Published Date: February 14, 2022
    Graphical Abstract
    • Abstract
  •   Objective  To observe the efficacy of venetoclax combined with hypomethylated drugs in the treatment of relapsed or refractory acute myeloid leukemia (AML).
      Methods  Clinical materials of 14 patients with relapsed or refractory AML in the Department of Hematology of the Northern Branch of Ruijin Hospital Affiliated to the Medical College of Shanghai Jiaotong University from January 2020 to August 2021 were analyzed retrospectively and followed up. Ten patients were treated with venetoclax and azacytidine, and the other four patients were treated with venetoclax and decitabine.
      Results  There were 5 cases with curative effect of complete remission (CR) or morphological CR with incomplete recovery of platelet count (CRi), 3 cases with partial remission (PR) and 6 cases with no remission (NR). Bone marrow suppression occurred in all the patients after treatment, and pulmonary infection was observed in 6 cases.
      Conclusion  The prognosis of patients with relapsed or refractory AML is poor. Venetoclax combined with hypomethylated drugs has a significant effect in some patients, which can achieve the CR result, and has better tolerance.
    • FullText(HTML)
    • References (23)
  • [1]
    DINARDO C D, RAUSCH C R, BENTON C, et al. Clinical experience with the Bcl-2inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies[J]. American Journal of Hematology, 2018, 93(3): 401-407. doi: 10.1002/ajh.25000
    [2]
    BYRNE M, DANIELSON N, SENGSAYADETH S, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia[J]. American Journal of Hematology, 2020, 95: 1006-1014. doi: 10.1002/ajh.25859
    [3]
    BEWERSDORF J P, GIRI S, WANG R, et al. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis[J]. Haematologica, 2020, 105(11): 242826.
    [4]
    DINARDO C D, JONAS B A, PULLARKAT V, et al. Azacitidine and venetoclax in Previously Untreated Acute Myeloid Leukemia[J]. New England Journal of Medicine, 2020, 383(7): 617-629. doi: 10.1056/NEJMoa2012971
    [5]
    DINARDO C D, PRATZ K, POTLURI J, et al. Durable Response with venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)[J]. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18(Suppl 1): S201.
    [6]
    MEI M, ALDOSS I, MARCUCCI G, et al. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use[J]. American Journal of Hematology, 2019, 94(3): 358-362.
    [7]
    AGARWAL S, GOPALAKRISHNAN S, MENSING S, et al. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis[J]. Hematological Oncology, 2019, 37(4): 464-473. doi: 10.1002/hon.2646
    [8]
    JONES A K, FREISE K J, AGARWAL S K, et al. Clinical Predictors of venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis[J]. Aaps Journal, 2016, 18(5): 1-11.
    [9]
    SALEM A H, DAVE N, MARBURY T, et al. Pharmacokinetics of the Bcl-2 Inhibitor venetoclax in Subjects with Hepatic Impairment[J]. Clinical Pharmacokinetics, 2019, 58(8): 1091-1100. doi: 10.1007/s40262-019-00746-4
    [10]
    FREISE K J, SHEBLEY M, SALEM A H. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model[J]. Journal of Clinical Pharmacology, 2017, 57(6): 796-804. doi: 10.1002/jcph.858
    [11]
    HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646. doi: 10.1016/j.cell.2011.02.013
    [12]
    WONG R S. Apoptosis in cancer: from pathogenesis to treatment[J]. Journal of Experimental & Clinical Cancer Research, 2011, 30(1): 87-87.
    [13]
    PFEFFER C M, ATK S. Apoptosis: A Target for Anticancer Therapy[J]. International Journal of Molecular Sciences, 2018, 19(2): 448-454. doi: 10.3390/ijms19020448
    [14]
    CROCE C M, REED J C. Finally, An Apoptosis-Targeting Therapeutic for Cancer[J]. Cancer Research, 2016, 76(20): 5914-5920. doi: 10.1158/0008-5472.CAN-16-1248
    [15]
    PRONIER E, ROSS L L. IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AMLs armour[J]. Cancer cell, 2015, 27(3): 323-325. doi: 10.1016/j.ccell.2015.02.013
    [16]
    MA J, ZHAO S J, QIAO X A, et al. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia[J]. Clin Cancer Res, 2019, 25(22): 6815-6826. doi: 10.1158/1078-0432.CCR-19-0832
    [17]
    ZHOU J D, ZHANG T J, XU Z J, et al. BCL-2 overexpression: clinical implication and biological insights in acute myeloid leukemia[J]. Diagnostic Pathology, 2019, 14(1): 68. doi: 10.1186/s13000-019-0841-1
    [18]
    STONE R M, MANDREKAR S J, SANFORD B L, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation[J]. N Engl J Med, 2017, 377(5): 454-454. doi: 10.1056/NEJMoa1614359
    [19]
    CORTES J E, SMITH B D, WANG E S. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS Phase 2 study results[J]. Npj Precision Oncology, 2018, 93(11): 1301-1310.
    [20]
    RAVANDI F, ASSI R, DAVER N, et al. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study[J]. The Lancet Haematology, 2019, 6(9): e480-e488. doi: 10.1016/S2352-3026(19)30114-0
    [21]
    PETERSDORF S H, KOPECKY K J, SLOVAK M, et al. A phase 3 study of gemtuzumabozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia[J]. Blood, 2013, 121(24): 4854-4860. doi: 10.1182/blood-2013-01-466706
    [22]
    CHONG C, ROBERTS A W, REYNOLDS J, et al. Chemotherapy and venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of venetoclax Combined With Modified Intensive Chemotherapy[J]. Journal of Clinical Oncology, 2020, 38(30): 3506-3517. doi: 10.1200/JCO.20.00572
    [23]
    ZHANG J, GU Y, CHEN B. Mechanisms of drug resistance in acute myeloid leukemia[J]. Onco Targets and therapy, 2019, 12: 1937-1945. doi: 10.2147/OTT.S191621
    • Related Articles

  • Related Articles

    [1]ZHU Shichun, TANG Ruze. Impact of radiotherapy on prognosis of children with high-risk neuroblastoma[J]. Journal of Clinical Medicine in Practice, 2023, 27(13): 16-19, 25. DOI: 10.7619/jcmp.20231480
    [2]REN Yanzhen, LI Ruixian, CHEN Jian'e, DU Zhichao, LOU Yuhua. Relationships of expression of uncoupling protein-2 with clinicopathological features and prognosis in patients with colorectal cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(23): 20-25. DOI: 10.7619/jcmp.20222104
    [3]HUANG Rong, FAN Bin, DING Jun. Correlation between expression of secretory clusterin and postoperative survival prognosis in paracancerous liver tissues of patients with resectable hepatocellular carcinoma[J]. Journal of Clinical Medicine in Practice, 2022, 26(8): 37-43. DOI: 10.7619/jcmp.20214996
    [4]LIU Dehui, YAN Yulan. Research progress of circRNAs in diagnosis and prognosis of lung cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(13): 124-128. DOI: 10.7619/jcmp.20211851
    [5]WANG Yang, GU Jiaxiang. Analysis in related influencing factors for survival rate of replantation of distal thumb amputation[J]. Journal of Clinical Medicine in Practice, 2021, 25(12): 90-92. DOI: 10.7619/jcmp.20210775
    [6]LI Bo, ZHANG Jie. Effects of doxorubicin combined with cisplatin on efficacy, survival rate and toxicity in cervical cancer patients with radiotherapy[J]. Journal of Clinical Medicine in Practice, 2020, 24(11): 108-110. DOI: 10.7619/jcmp.202011029
    [7]WANG Jinhua, PAN Jianxin, YANG Weixia. Clinical characteristics and survival status of patients with type 2 diabetes mellitus complicated with bacterial liver abscess[J]. Journal of Clinical Medicine in Practice, 2019, (3): 82-84,92. DOI: 10.7619/jcmp.201903022
    [8]YANG Qiang, WANG Xiang, MA Shenghui, LI Xin. Chemotherapy with oxaliplatin and tegafur gimeracil oteracil potassium capsule versus oxaliplatin-assisted xihuang capsules in the treatment of patients with advanced gastric cancer and its effects on T cell subsets,survival rate and adverse reactions[J]. Journal of Clinical Medicine in Practice, 2017, (17): 51-54. DOI: 10.7619/jcmp.201717015
    [9]REN Jinping, LI Song, TANG Kehu, SONG Yuanyuan, XU Jianbo. Influencing factors of survival rate in patients with myocardial infarction treated by intra-aortic balloon pump[J]. Journal of Clinical Medicine in Practice, 2017, (17): 39-41. DOI: 10.7619/jcmp.201717011

  • Cited by

    Periodical cited type(4)

    1. 沈利娜，邵海燕，骆晓婷，陈珊. 预防性应用头孢曲松和喹诺酮对高龄前列腺穿刺术患者全身炎症反应综合征的效果比较及影响因素. 中国药物与临床. 2024(05): 298-301 .
    2. 王书恒，李九智，高阳，刘彼得，雷鹏. 前列腺增生患者TUPKRP术后发生全身炎症反应综合征的危险因素分析. 保健医学研究与实践. 2024(07): 79-82+108 .
    3. 宋先初，刘明勋，蒋智. 次氯酸冲洗液预防经尿道前列腺电切术后感染的临床研究. 系统医学. 2024(22): 75-77 .
    4. 甘育涛，陈佳青. 右美托咪定辅助腰硬联合麻醉对老年经尿道前列腺电切术患者应激反应及炎症因子的影响. 药品评价. 2023(06): 769-772 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (272) PDF downloads (21) Cited by(4)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return